InvestorsHub Logo
Followers 4
Posts 372
Boards Moderated 0
Alias Born 08/13/2019

Re: eightisenough post# 224060

Sunday, 11/10/2019 11:56:05 AM

Sunday, November 10, 2019 11:56:05 AM

Post# of 425888

Atom--ezetimibe DIDN'T have the endorsements and its drug incorporated in the guidelines of all medical WHEN it received a crl. Vascepa--has endorsements and guidelines of ALL medical org.

NOW YOU SEE THE DIFFERENCE? an endorsement of the ada/aha AFTER fda crl could not help it in the fda initial evaluation.



And I'm saying when a drug is endorsed does not matter. A drug can still be prescribed off label. See ADA on ezetimibe. It is still in the current (2019) guidelines for cardiovascular disease even though it does not have a label for it:

10.24 For patients with diabetes and atherosclerotic cardiovascular disease, if LDL cholesterol is ≥70 mg/dL on maximally tolerated statin dose, consider adding additional LDL-lowering therapy (such as ezetimibe or PCSK9 inhibitor). A Ezetimibe may be preferred due to lower cost.



In other words, doctors can prescribe vascepa for primary prevention of cardiovascular disease off-label because it is within guidelines. Amarin, however, wants the label.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AMRN News